Editorial Policy — Clinical Content Standards

1. Purpose and Audience

All clinical and scientific content published on orvida.eu is written for licensed aesthetic medicine practitioners — including physicians, nurses, dentists and other regulated healthcare professionals who are authorised to administer injectable treatments in Portugal and Spain. This content is not intended for patients, consumers or the general public.

ORVIDA is the exclusive distributor of Sofiderm hyaluronic acid products (manufactured by Hangzhou Techderm Biological Products Co., Ltd.) for the Iberian Peninsula. Our editorial output supports professional decision-making: product selection, injection technique, patient safety and regulatory compliance. It does not constitute individualised medical advice for end patients.

2. Content Review Process

Content published on orvida.eu is authored by ORVIDA's clinical and regulatory team and reviewed against the following primary sources before publication:

• Primary scientific literature: claims referencing clinical outcomes, safety profiles or mechanism of action are supported by PubMed-indexed peer-reviewed studies. References are cited within articles where applicable.
• EU MDR 2017/745 and CE 2460 certification documentation: product-specific claims are verified against the manufacturer's CE certification dossier and the applicable requirements of Regulation (EU) 2017/745 on medical devices.
• Manufacturer technical dossiers: product specifications, rheological data and clinical indications are cross-referenced with the technical dossiers provided by Hangzhou Techderm Biological Products Co., Ltd., including Instructions for Use (IFU) and clinical evaluation reports.
• Applicable national guidance: content referencing prescribing rules, controlled-substance regulations or practitioner licensing requirements is reviewed against current INFARMED (Portugal) and AEMPS (Spain) guidance.

Where content describes treatment protocols or technique recommendations, those recommendations reflect the manufacturer's validated indications and the consensus of published professional guidelines. Off-label uses are clearly flagged as such.

3. Content Types

The following categories of content appear on orvida.eu. Each carries a specific review standard.

Blog articles

Practitioner-focused educational pieces covering technique, product science, anatomy, patient safety and regulatory updates. Articles cite primary literature and are reviewed by the clinical team for accuracy before publication. Authorship and publication date are stated on each article.

Clinical Q&As

Structured answers to practitioner questions on product use, dosing, contraindications and adverse-event management. Responses are drafted against IFU documentation and reviewed for alignment with current clinical evidence and INFARMED/AEMPS guidance.

Product specifications

Technical data sheets covering HA concentration, crosslinking technology, particle size, G’ values, needle gauge, recommended anatomical depth and CE marking status. All values are sourced directly from Hangzhou Techderm technical dossiers and are updated following any manufacturer change notification.

Regulatory guides

Summaries of EU MDR obligations, vigilance reporting requirements, cold-chain requirements and national licensing rules relevant to practitioners and clinic operators in Portugal and Spain. These guides are reviewed against the applicable regulation text and competent authority guidance, and updated whenever significant regulatory changes are published.

4. Update Policy

Content on orvida.eu is reviewed on the following schedule:

• Annual review: all published clinical articles are reviewed at least once per calendar year to verify ongoing accuracy against current literature and regulatory status.
• Event-triggered review: content is reviewed and updated immediately when new clinical evidence materially changes the safety or efficacy picture, when a regulatory body publishes updated guidance, or when the manufacturer issues a field safety notice or technical dossier amendment.
• Last-reviewed date: each article displays the date it was last reviewed. Where the review resulted in substantive changes, a revision note is appended at the end of the article.

Outdated content that cannot be updated in a timely manner is removed from public access pending revision.

5. Questions and Corrections

If you identify a factual error, a claim that requires a citation, or content that you believe is out of date, please contact us at info@orvida.eu with the subject line "Editorial correction".

We aim to acknowledge correction requests within five business days. Substantiated corrections are applied within 30 days of receipt, and the article's revision note is updated accordingly. We welcome feedback from practitioners who work with these products daily — your clinical experience strengthens the accuracy of our content.

6. Disclaimer

The content published on orvida.eu is intended solely for qualified healthcare professionals operating within a regulated practice setting. It is provided for informational and educational purposes related to the professional use of Sofiderm medical devices.

This content is not patient guidance and does not constitute medical advice. It must not be used by patients or consumers to make decisions about their own treatment. Treatment decisions should always be made by a qualified practitioner following a clinical assessment of the individual patient.

ORVIDA distributes Sofiderm products exclusively to verified B2B customers (clinics and licensed practitioners). No content on this website is intended to promote or solicit treatment from consumers or to circumvent the practitioner-patient relationship.